FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127293> ?p ?o ?g. }

• W4310127293 endingPage "8421" @default.
• W4310127293 startingPage "8420" @default.
• W4310127293 abstract "Background Cancer therapy induced thrombopenia (CTIT) refer to thrombopenia caused by various anti-cancer therapy which include chemotherapy, radiotherapy, targeted therapy and immunotherapy. Chemotherapy-induced thrombopenia (CIT) could increase the risk of bleeding, modification of treatment, cost of treatment and even influence overall survival. Recombinant human thrombopoietin (rhTPO) was approved for CIT by national medical products administration (NMPA). However, certain patients still could not benefit from these agents. Hetrombopag, a new orally active small molecule thrombopoietin receptor agonist (TPO-RA), acts through binding to thrombopoietin receptor to stimulate multiple intracellular signaling pathways, including JAK/STAT, PI3K/AKT and ERK1/2. This will stimulate the proliferation and differentiation of megakaryocytes and promote platelet production. Combination of TPO-RA and rhTPO is anticipated to improve the outcome compared with rhTPO alone for treating CTIT in cancer patients. Methods Between January 2021 and June 2022, we conducted a retrospective analysis of patients (18 - 80 years) with cancer therapy induced thrombopenia (platelet count < 50 x 109/L) treated with rhTPO (subcutaneous injection, 300 U/kg/d) alone or combination of rhTPO and hetrombopag (oral, 5 mg/d) at Beijing Luhe Hospital, Capital Medical University. Treatment will discontinue when platelet count increased more than 50 x 109/L or platelet count doubled than baseline. The maximum treatment was 14 days. Results In total, 58 patients were included for analysis (28 patients received rhTPO plus hetrombopag and 30 patients received rhTPO alone). The baseline characteristics were generally similar between two groups. Patients with baseline platelet count less than 30 x109/L were 28.6% vs 10% in rhTPO plus hetrombopag group and rhTPO alone group, respectively. There were 21 patients (75.0%) vs 9 patients (30.0%) achieved response (platelet count increased more than 50 x 109/L or doubled than baseline or reached more than 100 x 109/L without platelet transfusion) within 7-day treatment in rhTPO plus hetrombopag group and rhTPO alone group, respectively. Furthermore, 11 patients (39.3%) and 3 patients (10.0%) reached platelet count ≥100 x 109/L in rhTPO plus hetrombopag group and rhTPO alone group (Table 1). The median platelet count at baseline in two groups were similar. The platelet count of post treatment in two groups were both increased. While the platelet count increase in rhTPO plus hetrombopag group were higher than rhTPO group in day 3, day 5, day 7 and day 9 after treatment (Figure 1). Median time of treatment was 6.5 days (range 4-13) for rhTPO plus hetromnopag group and 9.5 days (range 5-14) for rhTPO group (P < 0.0001). One patient (3.3%) in rhTPO group reported bleeding (WHO bleeding grade 2) while no bleeding events were reported in rhTPO plus hetrombopag group. Five patients (16.7%) and three patients (10.7%) in rhTPO group and rhTPO plus hetrombopag group received platelet transfusion. Cancer patients treated with rhTPO or rhTPO plus hetrombopag were well tolerated, the treatment related adverse events were mainly alanine aminotransferase/aspartate aminotransferase increase or total bilirubin increased (all grade 1/2). The incidence of such adverse event was not significantly different between two groups. Conclusion Compared with rhTPO, combined rhTPO with hetrombopag for treating cancer therapy induced thrombopenia showed faster and deeper response without raise the safety concern. Further study needed to consolidate this result. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127293 created "2022-11-30" @default.
• W4310127293 creator A5006655487 @default.
• W4310127293 creator A5011497202 @default.
• W4310127293 creator A5024413298 @default.
• W4310127293 creator A5025007434 @default.
• W4310127293 creator A5029315541 @default.
• W4310127293 creator A5042265572 @default.
• W4310127293 creator A5045549905 @default.
• W4310127293 creator A5048025879 @default.
• W4310127293 creator A5049322951 @default.
• W4310127293 creator A5065693501 @default.
• W4310127293 creator A5073531557 @default.
• W4310127293 creator A5082816482 @default.
• W4310127293 creator A5085201914 @default.
• W4310127293 creator A5088586336 @default.
• W4310127293 date "2022-11-15" @default.
• W4310127293 modified "2023-09-28" @default.
• W4310127293 title "Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia" @default.
• W4310127293 doi "https://doi.org/10.1182/blood-2022-164490" @default.
• W4310127293 hasPublicationYear "2022" @default.
• W4310127293 type Work @default.
• W4310127293 citedByCount "0" @default.
• W4310127293 crossrefType "journal-article" @default.
• W4310127293 hasAuthorship W4310127293A5006655487 @default.
• W4310127293 hasAuthorship W4310127293A5011497202 @default.
• W4310127293 hasAuthorship W4310127293A5024413298 @default.
• W4310127293 hasAuthorship W4310127293A5025007434 @default.
• W4310127293 hasAuthorship W4310127293A5029315541 @default.
• W4310127293 hasAuthorship W4310127293A5042265572 @default.
• W4310127293 hasAuthorship W4310127293A5045549905 @default.
• W4310127293 hasAuthorship W4310127293A5048025879 @default.
• W4310127293 hasAuthorship W4310127293A5049322951 @default.
• W4310127293 hasAuthorship W4310127293A5065693501 @default.
• W4310127293 hasAuthorship W4310127293A5073531557 @default.
• W4310127293 hasAuthorship W4310127293A5082816482 @default.
• W4310127293 hasAuthorship W4310127293A5085201914 @default.
• W4310127293 hasAuthorship W4310127293A5088586336 @default.
• W4310127293 hasBestOaLocation W43101272931 @default.
• W4310127293 hasConcept C104317684 @default.
• W4310127293 hasConcept C109159458 @default.
• W4310127293 hasConcept C121608353 @default.
• W4310127293 hasConcept C126322002 @default.
• W4310127293 hasConcept C170493617 @default.
• W4310127293 hasConcept C203014093 @default.
• W4310127293 hasConcept C2776915898 @default.
• W4310127293 hasConcept C2777863708 @default.
• W4310127293 hasConcept C2778713057 @default.
• W4310127293 hasConcept C2778938600 @default.
• W4310127293 hasConcept C2780588981 @default.
• W4310127293 hasConcept C28328180 @default.
• W4310127293 hasConcept C2993327898 @default.
• W4310127293 hasConcept C40767141 @default.
• W4310127293 hasConcept C502942594 @default.
• W4310127293 hasConcept C54355233 @default.
• W4310127293 hasConcept C55493867 @default.
• W4310127293 hasConcept C71924100 @default.
• W4310127293 hasConcept C86803240 @default.
• W4310127293 hasConcept C89560881 @default.
• W4310127293 hasConceptScore W4310127293C104317684 @default.
• W4310127293 hasConceptScore W4310127293C109159458 @default.
• W4310127293 hasConceptScore W4310127293C121608353 @default.
• W4310127293 hasConceptScore W4310127293C126322002 @default.
• W4310127293 hasConceptScore W4310127293C170493617 @default.
• W4310127293 hasConceptScore W4310127293C203014093 @default.
• W4310127293 hasConceptScore W4310127293C2776915898 @default.
• W4310127293 hasConceptScore W4310127293C2777863708 @default.
• W4310127293 hasConceptScore W4310127293C2778713057 @default.
• W4310127293 hasConceptScore W4310127293C2778938600 @default.
• W4310127293 hasConceptScore W4310127293C2780588981 @default.
• W4310127293 hasConceptScore W4310127293C28328180 @default.
• W4310127293 hasConceptScore W4310127293C2993327898 @default.
• W4310127293 hasConceptScore W4310127293C40767141 @default.
• W4310127293 hasConceptScore W4310127293C502942594 @default.
• W4310127293 hasConceptScore W4310127293C54355233 @default.
• W4310127293 hasConceptScore W4310127293C55493867 @default.
• W4310127293 hasConceptScore W4310127293C71924100 @default.
• W4310127293 hasConceptScore W4310127293C86803240 @default.
• W4310127293 hasConceptScore W4310127293C89560881 @default.
• W4310127293 hasIssue "Supplement 1" @default.
• W4310127293 hasLocation W43101272931 @default.
• W4310127293 hasOpenAccess W4310127293 @default.
• W4310127293 hasPrimaryLocation W43101272931 @default.
• W4310127293 hasRelatedWork W1882300460 @default.
• W4310127293 hasRelatedWork W1999288154 @default.
• W4310127293 hasRelatedWork W2024861716 @default.
• W4310127293 hasRelatedWork W2065811219 @default.
• W4310127293 hasRelatedWork W2532650010 @default.
• W4310127293 hasRelatedWork W2557816942 @default.
• W4310127293 hasRelatedWork W2895332709 @default.
• W4310127293 hasRelatedWork W4223948263 @default.
• W4310127293 hasRelatedWork W4231315494 @default.
• W4310127293 hasRelatedWork W4256075833 @default.
• W4310127293 hasVolume "140" @default.
• W4310127293 isParatext "false" @default.
• W4310127293 isRetracted "false" @default.
• W4310127293 workType "article" @default.